Parameter |
SHS-PWLD EO-PE (N=56) |
SHS-PWLD LO-PE (N=97) |
SHS-PWLD NTN-P (N=95) |
p-value |
OHS-PWLD EO-PE (N=14) |
OHS-PWLD LO-PE (N=30) |
OHS-PWLD NTN-P (N=206) |
p-value |
10-20 weeks gestation (W1) |
|
|
|
|
|
|
|
|
GA (weeks) |
17.0(15.3-18.0) |
17.0(16.0-18.0) |
18.0(15.0-19.0) |
0.6930 |
17.0(15.8-18.0) |
18.0(16.0-18.0) |
17.0(16.0-18.0) |
0.7259 |
SBP (mmHg) |
123.0(120.0-128.8) * |
117.0(108.0-125.5) * |
113.0(105.0-120.0) |
<0.001 |
108.5(102.3-121.5) |
119.5(108.8-122.5) |
114.0(106.0-120.0) |
0.1504 |
DBP (mmHg) |
77.0(69.0-84.0) * |
76.0(67.0-82.5) * |
69.0(64.0-76.0) |
<0.001 |
70.5(67.0-78.0) |
72.0(66.8-82.0) |
70.0(66.0-78.0) |
0.6262 |
Serum PlGF (pg/mL) |
81.3(50.2-95.0) * |
87.3(68.5-95.3) * |
99.4(91.1-107.4) |
<0.001 |
85.6(59.2-97.3) ǂ |
93.9(58.8-100.5) ǂ |
100.5(90.5-109.4) |
<0.001 |
Serum VEGF-A (pg/mL) |
117.8(95.8-150.9) * |
121.0(92.1-170.2) * |
187.3
(170.1-204.2) |
<0.001 |
120.6(90.2-147.4) ǂ |
161.5(103.8-184.9) ǂ |
187.5 (170.1-196.3) |
<0.001 |
Serum sEng (ng/mL) |
7.0(5.8-9.3) * |
5.9(4.3-8.5) * |
4.1(3.2-5.1) |
<0.001 |
6.4(4.3-8.2) ǂ |
5.5(3.1-8.03) ǂ |
4.1(3.1-5.5) |
<0.001 |
Serum sFlt-1 (pg/mL) |
897.5(624.9-1100) * |
770.2(582.9-966.4) * |
543.0(433.3-682.4) |
<0.001 |
794.1(553.9-945.0) ǂ |
616.3(506.4-752.6) ǂ |
533.9(434.0-660.9) |
<0.001 |
Serum 8-epiPGF2α (pg/mL) |
600.0(499.2-667.6) * |
506.8(391.9-668.7) * |
371.9 (291.7-465.8) |
<0.001 |
535.8(364.9-641.2) ǂ |
399.1(350.0-506.5) ǂ |
360.1(297.8-451.7) |
<0.001 |
Urinary 8-OHdG (ng/mg Cr) |
87.75(81.6-99.4) * |
86.6(77.6-96.1) * |
75.20(51.3-86.1) |
<0.001 |
87.5(79.6-88.8) ǂ |
86.5(83.5-95.5) ǂ |
76.50(54.4-85.5) |
<0.001 |
Serum 8-OHdG (ng/L) |
88.0(81.2-96.1) * |
83.3(74.8-92.8) * |
73.1(48.9-82.2) |
<0.001 |
84.0(79.3-93.5) ǂ |
81.6(71.4-85.9) ǂ |
73.1(50.9-82.1) |
<0.001 |
Plasma TAC (µmol/L) |
147.6(94.6-259.3) * |
220.0(170.1-275.6) * |
234.6(180.3-317.2) |
<0.001 |
220.5(196.7-282.7) ǂ |
235.2(175.4-330.2) ǂ |
249.2(179.0-315.3) |
<0.001 |
sFlt-1/PlGF ratio |
10.1(7.7-13.4) * |
9.8(6.8-13.5) * |
4.4(3.5-5.9) |
<0.001 |
8.8(6.4-12.9) ǂ |
8.2(5.7-10.4) ǂ |
4.1(2.9-5.3) |
<0.001 |
8-epiPGF2alpha/PlGF ratio |
7.4(5.6-9.4) * |
6.9(4.9-9.6) * |
3.4(2.7-4.5) |
<0.001 |
5.9(4.3-10.5) ǂ |
5.8(3.8-6.9) ǂ |
3.7(2.8-4.8) |
<0.001 |
8-OHdG/PlGF ratio |
1.1(0.8-1.6) * |
0.9(0.8-1.5) * |
0.8(0.4-0.8) |
<0.001 |
0.9(0.8-1.1) ǂ |
0.8(0.7-1.5) ǂ |
0.7(0.4-0.8) |
<0.001 |
sEng/PlGF ratio |
88.1(67.1-127.5) * |
80.8(50.7-131.4) * |
41.7(29.7-51.6) |
<0.001 |
71.9(40.2-100.8) ǂ |
69.8(47.2-116.9) ǂ |
41.8(30.0-54.8) |
<0.001 |
21-31 weeks gestation (W2) |
|
|
|
|
|
|
|
|
GA (weeks) |
27.5(26.0-28.0) |
28.0(26.0-28.0) |
28.0(26.0-28.0) |
0.9963 |
27.0(25.7-28.0) |
28.0(26.0-28.0) |
28.0(26.0-28.0) |
0.4607 |
SBP (mmHg) |
134.5(121.5-138.3) *¥ |
128.5(109.5-130.0) *‡ |
119.5(106.5-122.5) |
<0.001 |
120.0(110-124) ǂ |
121.0(110.3-124.0) ǂ |
116(108-121) |
0.1504 |
DBP (mmHg) |
88.5(70.5-85.5) * |
78(68.5-84.0) * |
73(65.5-77.5) |
<0.001 |
72.0(68.5-79.5) |
73.5(68.3-83.5) |
72.5(67.5-79.5) |
0.6262 |
Serum PlGF (pg/mL) |
98.3(61.2-111.7) * |
106.0(82.8-111.3) * |
132.3(117.9-181.5) |
<0.001 |
105.3(71.7-117.7) ǂ |
109.6(71.1-119.7) ǂ |
146.8(120.9-183.6) |
<0.001 |
Serum VEGF-A (pg/mL) |
152.6(109.1-210.0) * |
157.6(111.3-215.5) * |
280.3 (229.8-421.4) |
<0.001 |
189.0(126.0-226.9) ǂ |
198.6(126.0-215.9) ǂ |
288.3 (230.2-418.7) |
<0.001 |
Serum sEng (ng/mL) |
8.6(7.2-11.1) * |
7.5(5.7-10.3) * |
5.5(4.6-6.6) |
<0.001 |
8.1(5.8-9.9) ǂ |
7.0(4.4-9.8) ǂ |
5.5(4.4-6.9) |
<0.001 |
Serum sFlt-1 (pg/mL) |
1032(718.6-1265) * |
885.7(670.3-1111) * |
624.5(499.0-784.7) |
<0.001 |
913.2(636.9-1087) ǂ |
708.7(582.3-865.5) ǂ |
614.0(499.1-760.0) |
<0.001 |
Serum 8-epiPGF2α (pg/mL) |
963.7(803.9-1145) * |
826.8(625.2-1079) * |
593.3 (465.3-743.0) |
<0.001 |
854.6(582.2-1015) ǂ |
656.9(558.4-792.8) ǂ |
574.4(475.0-720.5) |
<0.001 |
Urinary 8-OHdG (ng/mg Cr) |
105.7(97.6-121.7) * |
103.3(92.4-114.7) * |
90.0(61.8-101.6) |
<0.001 |
103.0(97.8-113.2) ǂ |
102.1(93.9-104.5) ǂ |
90.4(64.6-99.9) |
<0.001 |
Serum 8-OHdG (ng/L) |
98.6(91.0-107.6) * |
94.1(85.7-104.6) * |
81.9(54.8-92.1) |
<0.001 |
94.0(89.8-104.7) ǂ |
91.3(79.9-97.4) ǂ |
81.9(56.9-91.9) |
<0.001 |
Plasma TAC (µmol/L) |
178.0(127.8-212.3) * |
205.7(146.4-253.0) * |
258.1(196.4-348.9) |
<0.001 |
189.5(142.6-239.6) ǂ |
210.6(177.1-230.1) ǂ |
274.1(196.9-346.8) |
<0.001 |
sFlt-1/PlGF ratio |
10.8(8.3-13.9) * |
10.3(7.2-14.2) * |
5.5(4.19-6.9) |
<0.001 |
9.0(6.7-13.5) ǂ |
8.6(6.0-10.2) ǂ |
4.9(3.9-6.7) |
<0.001 |
8-epiPGF2alpha/PlGF ratio |
9.7(7.5-12.2) * |
9.1(6.4-13.6) * |
3.9(2.8-5.0) |
<0.001 |
8.3(5.8-13.8) ǂ |
7.5(5.1-9.7) ǂ |
4.1(3.2-5.6) |
<0.001 |
8-OHdG/PlGF ratio |
1.0(0.7-1.4) * |
0.9(0.7-1.4) * |
0.5(0.4-0.7) |
<0.001 |
0.8(1.2-2.2) ǂ |
0.7(0.6-1.0) ǂ |
0.5(0.3-0.7) |
<0.001 |
sEng/PlGF ratio |
89.6(70.2-124.0) * |
89.2(57.1-133.7) * |
37.1(27.5-51.9) |
<0.001 |
80.7(45.2-112.4) ǂ |
75.9(56.6-120.7) ǂ |
41.4(28.2-53.1) |
<0.001 |